Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Int J Mol Sci. 2021 Oct 19;22(20):11267. doi: 10.3390/ijms222011267.
Molecular alterations drive cancer initiation and evolution during development and in response to therapy. Radiotherapy is one of the most commonly employed cancer treatment modalities, but radiobiologic approaches for personalizing therapy based on tumor biology and individual risks remain to be defined. In recent years, analysis of circulating nucleic acids has emerged as a non-invasive approach to leverage tumor molecular abnormalities as biomarkers of prognosis and treatment response. Here, we evaluate the roles of circulating tumor DNA and related analyses as powerful tools for precision radiotherapy. We highlight emerging work advancing liquid biopsies beyond biomarker studies into translational research investigating tumor clonal evolution and acquired resistance.
分子改变驱动癌症在发育过程中的起始和演进，并对治疗产生反应。放射疗法是最常用的癌症治疗方式之一，但基于肿瘤生物学和个体风险来个性化治疗的放射生物学方法仍有待确定。近年来，循环核酸分析已成为一种非侵入性方法，可以利用肿瘤分子异常作为预后和治疗反应的生物标志物。在这里，我们评估了循环肿瘤 DNA 及其相关分析作为精准放射治疗有力工具的作用。我们强调了将液体活检从生物标志物研究推进到转化研究中，以研究肿瘤克隆进化和获得性耐药的新兴工作。
